BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
It was really small. It was like 17 patients in the lead-in. But I think exciting in that, you know, the trial is... going forward. And there's multiple arms to that study. So they only showed the safety of the triplet. There's also a doublet with EV plus Dervalumab and then Dervalumab as adjuvant. And then the weird part is that the control arm is no therapy.
0
💬
0
Comments
Log in to comment.
There are no comments yet.